GeneOne Life Science Second Quarter 2025 Earnings: ₩187 loss per share (vs ₩39.00 loss in 2Q 2024)

Simply Wall St
KOSE:A011000 1 Year Share Price vs Fair Value
Explore GeneOne Life Science's Fair Values from the Community and select yours

GeneOne Life Science (KRX:011000) Second Quarter 2025 Results

Key Financial Results

  • Revenue: ₩6.81b (down 27% from 2Q 2024).
  • Net loss: ₩15.4b (loss widened by 20% from 2Q 2024).
  • ₩187 loss per share (further deteriorated from ₩39.00 loss in 2Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

KOSE:A011000 Earnings and Revenue History August 20th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

GeneOne Life Science shares are down 9.3% from a week ago.

Risk Analysis

Be aware that GeneOne Life Science is showing 3 warning signs in our investment analysis that you should know about...

Valuation is complex, but we're here to simplify it.

Discover if GeneOne Life Science might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.